-
DON Liver Injury: Mitophagy, p62-Keap1-Nrf2
2026-08-13
The reference study proposes that deoxynivalenol-induced liver injury results from excessive PINK1/Parkin-mediated mitophagy together with suppression of the p62-Keap1-Nrf2 antioxidant defense pathway. Its combined mouse, AML-12 cell, inhibitor, gene-silencing, and p62-overexpression design provides a mechanistic framework for studying mycotoxin hepatotoxicity, while the preprint status warrants careful interpretation and independent validation.
-
Phosphoenolpyruvate, cGAS, and Healthy Aging
2026-08-13
A 2026 Nature Aging study identifies phosphoenolpyruvate (PEP) as an endogenous brake on cGAS–STING-driven inflammation, with a biphasic age-related trajectory in mice and humans. The work connects glycolytic metabolism to inflammaging, neuroinflammation, and cognitive decline while offering a framework for testing metabolic interventions in aging models.
-
MG-132 and Z-LLL-al: Proteasome Workflows
2026-08-12
MG-132, also known as Z-LLL-al, gives researchers temporal control over proteasome-dependent protein accumulation, apoptosis, cell-cycle changes, and stress signaling. This practical guide connects dose-finding and validation workflows with a heterochromatin study that highlights why ubiquitination, ncRNA, and phase separation should be measured alongside proteasome activity.
-
CUDC-907: Practical PI3K/HDAC Workflow Guide
2026-08-11
CUDC-907 is a dual PI3K and HDAC inhibitor for controlled cell-based studies of PI3K/AKT signaling, histone acetylation, cell-cycle progression, and apoptosis. This dossier-based guide covers preparation, assay setup, and QC while emphasizing that the compound is for scientific research only, not diagnostic, therapeutic, or clinical use.
-
Macrophage EV–miR-660 Drives Breast Cancer Metastasis
2026-08-11
The reference study identifies a tumor-associated macrophage extracellular-vesicle pathway in which miR-660 suppresses KLHL21, releases IKKβ signaling, and activates NF-κB p65 to promote breast cancer invasion and metastasis. Its combination of patient-tissue analysis, cell perturbation, extracellular-vesicle co-culture, and mouse modeling provides a mechanistic framework for studying macrophage-to-tumor communication.
-
Lambda Protein Phosphatase for BMAL1 Studies
2026-08-10
Use Lambda Protein Phosphatase to test whether BMAL1 phosphorylation controls antibody recognition, protein mobility, and phase-separation behavior. This practical workflow combines broad serine, threonine, tyrosine, and histidine dephosphorylation with controls designed for circadian protein research.
-
APOC1 and Cyclopamine in Papillary Thyroid Carcinoma
2026-08-09
The reference study identifies APOC1 as a clinically relevant and functionally active contributor to papillary thyroid carcinoma progression, with links to proliferation, apoptosis resistance, and immune-evasion signatures. It further uses Connectivity Map analysis and complementary cell and mouse experiments to nominate Cyclopamine as a candidate treatment that produces a stronger response when APOC1 is depleted.
-
Melittin Workflows for GPCR and Cancer Research
2026-08-08
Melittin is a bioactive peptide for experimentally separating Gs- and Gi-linked signaling from downstream viability, migration, and cell-death effects. This practical guide translates glioblastoma findings into controlled assay workflows, with preparation parameters and troubleshooting steps for reproducible signal transduction and cancer biology research.
-
Filipin III in Cholesterol Assay Workflows
2026-08-07
Learn how Filipin III (SKU B6034) can complement viability, proliferation, and cytotoxicity assays by revealing membrane cholesterol distribution and microdomain changes. This scenario-based guide covers assay compatibility, handling, interpretation, and practical supplier selection using documented product properties and a 2026 cholesterol-homeostasis study.
-
Nonivamide (Capsaicin Analog): In Vivo Insights and Translat
2026-08-07
Explore how Nonivamide, a capsaicin analog and TRPV1 agonist, advances cancer and neurodermatitis research through unique in vivo mechanisms. This article delivers new perspectives on translational assay design and protocol optimization.
-
AMG 487 CXCR3 Antagonist: Precision in Macrophage Polarizati
2026-08-06
AMG 487 empowers researchers to dissect context-dependent CXCR3 signaling, revealing new levers for modulating inflammation and cell fate. This guide demystifies its use in autophagy and macrophage polarization workflows, with data-driven troubleshooting and protocol tips for robust experimental results.
-
One-step TUNEL Cy3 Apoptosis Detection Kit: Enhanced Assay P
2026-08-06
Elevate apoptosis detection in tissue and cell models with the One-step TUNEL Cy3 Apoptosis Detection Kit, which streamlines terminal deoxynucleotidyl transferase (TdT) labeling for sensitive, reproducible DNA fragmentation analysis. This article details optimized workflows, experimental insights, and troubleshooting strategies that set this APExBIO solution apart for robust apoptosis research.
-
CD36-Driven Lipid Metabolism Enables Immune Escape in AML
2026-08-05
Guo et al. uncover a non-canonical, CD36-dependent lipid metabolic program in AML that suppresses T cell activity and leads to resistance against hypomethylating therapy. Their findings elucidate the mechanistic synergy between exogenous lipid uptake and innate immune signaling in leukemia, highlighting new metabolic targets for immunotherapy.
-
Resveratrol's Hormetic Rescue of Radiation-Induced Endotheli
2026-08-05
This study establishes a robust in vitro endothelial model to investigate the hormetic effects of resveratrol on radiation-induced vascular injury. The findings clarify optimal dosing and mechanistic effects, providing a new platform for screening vascular protective agents and advancing preclinical radioprotection research.
-
Intravesical p21 mRNA-LNP: A New Approach for Bladder Cancer
2026-08-04
This study introduces a localized, non-viral mRNA therapy for bladder cancer by delivering chemically modified p21 mRNA via lipid nanoparticles directly into the bladder. The approach restores p21 tumor suppressor function in situ, suppresses tumor growth, and demonstrates favorable safety and specificity, offering a promising translational advance for non–muscle-invasive bladder cancer.